Evidence map›Paper›PMID 32563262›Full record

ArticleJournal of neuroinflammation2020

Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants.

Elisabeth Mulazzani, Danny Wagner, Joachim Havla, Miriam Schlüter, Ingrid Meinl, Lisa-Ann Gerdes, Tania Kümpfel

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elisabeth MulazzaniInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians University, Marchioninistraße 15, 81377, Munich, Germany.
Danny WagnerInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians University, Marchioninistraße 15, 81377, Munich, Germany.
Joachim HavlaInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians University, Marchioninistraße 15, 81377, Munich, Germany.
Miriam SchlüterInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians University, Marchioninistraße 15, 81377, Munich, Germany.
Ingrid MeinlInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians University, Marchioninistraße 15, 81377, Munich, Germany.
Lisa-Ann GerdesInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians University, Marchioninistraße 15, 81377, Munich, Germany.
Tania KümpfelInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians University, Marchioninistraße 15, 81377, Munich, Germany. tania.kuempfel@med.uni-muenchen.de.
Ludwig-Maximilians-Universität München · DE

Funding

Bundesministerium für Bildung und Forschung 01ZZ1603[A-D] and Z1804[A-H] (DIFUTURE)Deutsche Forschungsgemeinschaft EXC 1010 SyNergy
6 · The paper itself

Abstract

backgroundNeurological manifestations and the co-occurrence of multiple sclerosis (MS) have been reported in patients with autoinflammatory diseases (AID) and variants of the NLRP3-, MEFV-, or TNFRSF1A gene. However, type and frequency of neurological involvement are widely undetermined.

methodsWe assessed clinical characteristics of 151 (108 with MS) patients carrying NLRP3-, MEFV- and TNFRSF1A low-penetrance variants  from the Institute of Clinical Neuroimmunology. We evaluated demographic, genetic, and clinical features with a focus on central nervous system (CNS) involvement including magnetic resonance imaging (MRI) results and cerebrospinal fluid (CSF) data. The disease course of AID patients with MS was compared to a matched MS control group without mutations.

resultsThe genetic distribution comprised 36 patients (23%) with NLRP3- and 66 patients (43%) with TNFRSF1A low-penetrance variants as well as 53 (34%) patients carrying pathogenic mutations or low-penetrance variants in the MEFV gene. MS patients displayed most frequently the R92Q TNFRSF1A variant (n = 51; 46%) followed by the Q703K NLRP3 variant (n = 15; 14%) and the E148Q substitution (n = 9; 8%) in the MEFV gene. The disease course of MS was not influenced by the genetic variants and did not differ from MS patients (n = 51) without mutations. AID patients without MS most frequently harbored MEFV mutations (n = 19, 43%) followed by NLRP3- (n = 17, 39%) and TNFRSF1A (n = 8, 18%) low-penetrance variants. Sixteen (36%) of them suffered from severe CNS involvement predominantly recurrent aseptic meningoencephalitis and optic neuritis accompanied by abnormal MRI and CSF results. Severe CNS inflammation was associated with the Q703K allele. Headache was a highly prevalent neurological symptom (up to 74%), irrespective of the underlying genetic variation. The NLRP3 cohort without MS more frequently exhibited affections of the cranial nerves (CN) (p = 0.0228) and motor symptoms (p = 0.0455). Elevated acute-phase reactants were detected in all patients, and fever episodes were present in up to 50%. Arthralgias were the most frequently identified constitutional symptom among all subgroups.

conclusionsOur data highlight the high prevalence of neurological manifestations, including concomitant MS, among NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants. In particular, patients carrying the Q703K NLRP3 variant are at risk for severe CNS inflammation and CN affection.

Indexed as

AdultAgedAllelesDNA Mutational AnalysisFamilial Mediterranean FeverFemaleGenetic Predisposition to DiseaseHeadacheHumansMaleMiddle AgedMultiple SclerosisMutationNLR Family, Pyrin Domain-Containing 3 ProteinOptic NeuritisPenetranceNLR Family, Pyrin Domain-Containing 3 ProteinPyrinReceptors, Tumor Necrosis Factor, Type IAutoimmunityAutoinflammationCAPSFMFMultiple sclerosisTRAPS

Identifiers

PMID32563262
PMCPMC7306142
OpenAlexW3036643861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.